news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

on september 5, minsheng health (stock code: 301507), inherited as "one of the four major western medicines", celebrated its first anniversary of listing.

in the past year since its listing on the gem, minsheng health has delivered satisfactory results, achieved comprehensive growth in business scale and continuous improvement in profitability, and set a new benchmark in the industry with its solid operating results.

the financial report shows that minsheng health released its 2024 semi-annual operating results. the semi-annual report shows that in the first half of 2024, minsheng health achieved operating income of 397.4356 million yuan, a year-on-year increase of 8.06%; net profit attributable to shareholders of the parent was 77.2694 million yuan, a year-on-year increase of 10.30%.

source: photo network

focusing on the "four new strategies", we build four core businesses

on september 3-4, to celebrate the first anniversary of its listing on the growth enterprise market, minsheng health held an exchange activity with the theme of "new health choices, new breakthroughs in categories". minsheng health chairman zhu fujiang, general manager zhang haijun and other leaders attended the event.

zhu fujiang said that since its listing, minsheng health has optimized its business layout around the four new strategies of "new products, new businesses, new models and new projects" while focusing on its core business, and has built four core business segments, namely 21 jinvita, purebao, minsheng health and minsheng tongchun, covering multiple market segments such as vitamins and minerals, probiotics, therapeutic otc drugs, and big health, and has fully entered the big health industry.